Here’s my summary of new data to look forward to from IAS 2019.
Why IAS 2019 data provided me with new tools for my practice and a sense of hope that we can beat HIV.
Patient-reported outcomes on long-acting injectable cabotegravir plus rilpivirine reinforce high treatment acceptance and satisfaction. Here’s my take on what this means for patients and practice.
Download slide highlights of key studies addressing current issues in HIV care, as reported at this important annual conference.
Listen to downloadable audio from a live Webinar reviewing the most clinically relevant new HIV data on NTD risk in pregnancy, PrEP, first-line therapy, and switch strategies.
In this downloadable audio from a live Webinar, gain clinical insights on new HIV data presented at IAS 2019. Areas of focus include NTD risk in pregnancy, PrEP, first-line therapy, switch strategies, and STI prevalence among MSM.
Updated first-line and switch data reinforce the noninferiority of DTG/3TC compared with 3-drug regimens. How will these results affect practice? Here’s my take.
Updated information regarding neural tube defects and weight gain with ART was presented at IAS 2019. These data are important to my practice. Here’s why.
IAS 2019 conference organizers are using social media to communicate with delegates attending the meeting and with those following the conference from home.
Join the #IAS2019 conversation
For more information about these resources and IAS 2019, go to www.ias2019.org.
NAM is the official provider of online scientific news reporting for IAS 2019 via its Web site and summary email bulletins during the conference.
To view the coverage and to sign up for the bulletins (also available in French, Portuguese, Spanish, and Russian), go to www.aidsmap.com.